Drug Profile
MEN 1112
Alternative Names: ADC-001; MEN1112; MEN1112/OBT357; OBT357; OX 357; OX-001Latest Information Update: 03 Aug 2021
Price :
$50
*
At a glance
- Originator Menarini; Oxford BioTherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 03 Aug 2021 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in Spain, Germany, Italy, France, Belgium, before August 2021 (IV) (Menarini pipeline, August 2021)
- 10 Apr 2021 Preclinical trials in Myelodysplastic syndromes in Italy (unspecified route)
- 10 Apr 2021 Pharmacodynamics data from a preclinical studies in Acute myeloid leukemia presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)